⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INKT News
MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
globenewswire.com
INKT
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
globenewswire.com
INKT
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
globenewswire.com
INKT
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
globenewswire.com
INKT
Form 8-K
sec.gov
INKT
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
globenewswire.com
INKT
Form 8-K
sec.gov
INKT
Form 8-K
sec.gov
INKT
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
globenewswire.com
INKT
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
globenewswire.com
INKT